Format

Send to

Choose Destination
Am J Psychiatry. 2005 Dec;162(12):2379-81.

Open-label trial of riluzole in generalized anxiety disorder.

Author information

1
Department of Biological Psychiatry, New York State Psychiatric Institute, USA. sanjay.mathew@mssm.edu

Abstract

OBJECTIVE:

There is a need to identify novel pharmacotherapies for anxiety disorders. The authors examined the safety and efficacy of riluzole, an antiglutamatergic agent, in adult outpatients with generalized anxiety disorder.

METHOD:

In an 8-week, open-label, fixed-dose study, 18 medically healthy patients with DSM-IV generalized anxiety disorder received treatment with riluzole (100 mg/day) following a 2-week drug-free period. The primary efficacy measure was the Hamilton Anxiety Rating Scale (HAM-A) score at endpoint.

RESULTS:

Twelve of the 15 patients who completed the trial responded positively to riluzole. At 8 weeks, eight of the 15 patients had HAM-A score indicating remission of their anxiety. The median time to response was 2.5 weeks.

CONCLUSIONS:

Riluzole appears to be an effective, well-tolerated, and rapidly acting anxiolytic medication for some patients with generalized anxiety disorder. Larger, placebo-controlled studies are indicated.

PMID:
16330605
DOI:
10.1176/appi.ajp.162.12.2379
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center